Published in Int J Lab Hematol on November 30, 2009
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
Multiple functional domains in the adenovirus E1A gene. Cell (1987) 4.22
TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell (1990) 3.55
Identification of separate domains in the adenovirus E1A gene for immortalization activity and the activation of virus early genes. Mol Cell Biol (1986) 3.52
Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med (1992) 3.21
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300. Genes Dev (1995) 2.93
Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth. J Virol (1993) 2.92
Phosphate is a specific signal for induction of osteopontin gene expression. Proc Natl Acad Sci U S A (2000) 2.59
Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med (1993) 2.52
Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost (2005) 2.46
Domains of the adenovirus E1A protein required for oncogenic activity are also required for dissociation of E2F transcription factor complexes. Genes Dev (1991) 2.40
Different functional domains of the adenovirus E1A gene are involved in regulation of host cell cycle products. Mol Cell Biol (1987) 2.38
Lytic and transforming functions of individual products of the adenovirus E1A gene. J Virol (1986) 2.14
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant (2009) 2.03
Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant (2007) 2.03
Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Bone Marrow Transplant (1998) 1.87
Proteasome inhibitors: antitumor effects and beyond. Leukemia (2006) 1.87
Simian virus 40 large-T antigen expresses a biological activity complementary to the p300-associated transforming function of the adenovirus E1A gene products. Mol Cell Biol (1991) 1.85
p300, and p300-associated proteins, are components of TATA-binding protein (TBP) complexes. Oncogene (1993) 1.76
Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood (1996) 1.70
CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res (1997) 1.70
Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica (2000) 1.66
Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med (1999) 1.65
Gene array analysis of osteoblast differentiation. Cell Growth Differ (2001) 1.64
Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality. Bone Marrow Transplant (2007) 1.63
Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol (2000) 1.55
The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity. Mol Cell Biol (2000) 1.54
Analysis with specific polyclonal antiserum indicates that the E1A-associated 300-kDa product is a stable nuclear phosphoprotein that undergoes cell cycle phase-specific modification. Mol Cell Biol (1991) 1.52
Relationship between alkaline phosphatase levels, osteopontin expression, and mineralization in differentiating MC3T3-E1 osteoblasts. J Cell Biochem (1998) 1.51
Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant (2007) 1.47
p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes. Mol Cell Biol (1998) 1.47
Characterization of monoclonal antibodies raised against p300: both p300 and CBP are present in intracellular TBP complexes. J Virol (1997) 1.45
The spectrum of mutations in TBX3: Genotype/Phenotype relationship in ulnar-mammary syndrome. Am J Hum Genet (1999) 1.41
E1A induces phosphorylation of the retinoblastoma protein independently of direct physical association between the E1A and retinoblastoma products. Mol Cell Biol (1991) 1.41
The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev (1990) 1.40
Heterotopic ossification after primary cemented and noncemented total hip arthroplasty in patients with osteoarthritis and rheumatoid arthritis. Can J Surg (1994) 1.40
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. Haematologica (1999) 1.39
Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant (2001) 1.39
Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol (1999) 1.39
Promoter-specific trans-activation by the adenovirus E1A12S product involves separate E1A domains. Mol Cell Biol (1992) 1.37
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant (1994) 1.33
DNA-binding properties of the E1A-associated 300-kilodalton protein. Mol Cell Biol (1992) 1.31
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
Gambling as a form of dependence. Br J Addict Alcohol Other Drugs (1970) 1.29
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol (1999) 1.26
Comparison of five methods for the assay of serum gentamicin. Antimicrob Agents Chemother (1981) 1.25
Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood (2001) 1.24
Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant (2009) 1.21
Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2007) 1.21
Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia (2007) 1.20
Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant (2008) 1.20
Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant (2002) 1.20
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene (2007) 1.18
E1A promotes association between p300 and pRB in multimeric complexes required for normal biological activity. J Virol (1995) 1.17
Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol (2002) 1.15
Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc Natl Acad Sci U S A (1999) 1.15
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia (2009) 1.14
Cytogenetic follow-up after bone marrow transplantation for Philadelphia-positive chronic myeloid leukemia. Cancer Genet Cytogenet (1989) 1.14
Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol (2001) 1.14
Synthesis of p34, the mammalian homolog of the yeast cdc2+/CDC28 protein kinase, is stimulated during adenovirus-induced proliferation of primary baby rat kidney cells. Oncogene (1988) 1.12
Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Ann Oncol (2010) 1.12
Meningococcal vaccines--present and future. Trans R Soc Trop Med Hyg (1991) 1.11
Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant (2003) 1.11
Immune suppression of hematopoiesis in aplastic anemia: activity of T-gamma lymphocytes. J Immunol (1980) 1.11
Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia (1997) 1.10
Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol (2000) 1.09
The influence of cyclosporin alone, or cyclosporin and methotrexate, on the incidence of mixed haematopoietic chimaerism following allogeneic sibling bone marrow transplantation for severe aplastic anaemia. Bone Marrow Transplant (2006) 1.08
Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother (2012) 1.08
Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. J Natl Cancer Inst (1984) 1.07
Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood (1992) 1.07
Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.07
Inactivation of neutrophil-derived hypochlorous acid by nimesulide: a potential mechanism for the tissue protection during inflammation. Int J Tissue React (1990) 1.07
Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant (2003) 1.06
Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. Cancer (1983) 1.06
Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. The Chilean National Committee for Meningococcal Disease. NIPH Ann (1991) 1.05
Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta Haematol (1993) 1.05
Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res (1985) 1.04
Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol (2005) 1.03